126 related articles for article (PubMed ID: 23077022)
1. MicroRNAs in the CSF: macro-advance in MS?
Meinl E; Meister G
Neurology; 2012 Nov; 79(22):2162-3. PubMed ID: 23077022
[No Abstract] [Full Text] [Related]
2. Regulated microRNAs in the CSF of patients with multiple sclerosis: a case-control study.
Haghikia A; Haghikia A; Hellwig K; Baraniskin A; Holzmann A; Décard BF; Thum T; Gold R
Neurology; 2012 Nov; 79(22):2166-70. PubMed ID: 23077021
[TBL] [Abstract][Full Text] [Related]
3. Multiple sclerosis: predicting risk and delaying progression.
Yeh EA; Weinstock-Guttman B
Lancet Neurol; 2010 Jan; 9(1):7-9. PubMed ID: 20083024
[No Abstract] [Full Text] [Related]
4. Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis.
Fenoglio C; Ridolfi E; Cantoni C; De Riz M; Bonsi R; Serpente M; Villa C; Pietroboni AM; Naismith RT; Alvarez E; Parks BJ; Bresolin N; Cross AH; Piccio LM; Galimberti D; Scarpini E
Mult Scler; 2013 Dec; 19(14):1938-42. PubMed ID: 24277735
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic aspects of multiple sclerosis and future therapeutic options.
Jamebozorgi K; Rostami D; Pormasoumi H; Taghizadeh E; Barreto GE; Sahebkar A
Int J Neurosci; 2021 Jan; 131(1):56-64. PubMed ID: 32075477
[TBL] [Abstract][Full Text] [Related]
6. Multiple sclerosis: putting two and two together.
Trowsdale J
Nat Med; 2006 Oct; 12(10):1119-21. PubMed ID: 17024201
[No Abstract] [Full Text] [Related]
7. Cannabinoids and B cells: emerging targets for treating progressive multiple sclerosis.
Giovannoni G
Mult Scler; 2011 Mar; 17(3):259-61. PubMed ID: 21362756
[No Abstract] [Full Text] [Related]
8. Gene expression profiling in MS: a fulfilled promise?
Baranzini SE
Mult Scler; 2013 Dec; 19(14):1813-4. PubMed ID: 24277731
[No Abstract] [Full Text] [Related]
9. Biomarkers for MS: unpuzzling the progressive multiple sclerosis puzzle.
Fox RJ
Neurology; 2014 Oct; 83(17):1488-9. PubMed ID: 25253742
[No Abstract] [Full Text] [Related]
10. Role of genetic susceptibility variants in predicting clinical course in multiple sclerosis: a cohort study.
Pan G; Simpson S; van der Mei I; Charlesworth JC; Lucas R; Ponsonby AL; Zhou Y; Wu F; Taylor BV
J Neurol Neurosurg Psychiatry; 2016 Nov; 87(11):1204-1211. PubMed ID: 27559181
[TBL] [Abstract][Full Text] [Related]
11. Increase in CCR5 Delta32/Delta32 genotype in multiple sclerosis.
Pulkkinen K; Luomala M; Kuusisto H; Lehtimäki T; Saarela M; Jalonen TO; Elovaara I
Acta Neurol Scand; 2004 May; 109(5):342-7. PubMed ID: 15080861
[TBL] [Abstract][Full Text] [Related]
12. A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis.
Gilbert GJ
Neurology; 2015 May; 84(21):2201. PubMed ID: 26009563
[No Abstract] [Full Text] [Related]
13. Hypermethylation of MIR21 in CD4+ T cells from patients with relapsing-remitting multiple sclerosis associates with lower miRNA-21 levels and concomitant up-regulation of its target genes.
Ruhrmann S; Ewing E; Piket E; Kular L; Cetrulo Lorenzi JC; Fernandes SJ; Morikawa H; Aeinehband S; Sayols-Baixeras S; Aslibekyan S; Absher DM; Arnett DK; Tegner J; Gomez-Cabrero D; Piehl F; Jagodic M
Mult Scler; 2018 Sep; 24(10):1288-1300. PubMed ID: 28766461
[TBL] [Abstract][Full Text] [Related]
14. Relapsing-remitting and primary progressive MS have the same cause(s)--the neuropathologist's view: 2.
Kuhlmann T
Mult Scler; 2013 Mar; 19(3):268-9. PubMed ID: 23426170
[No Abstract] [Full Text] [Related]
15. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis.
Ge Y; Grossman RI; Udupa JK; Wei L; Mannon LJ; Polansky M; Kolson DL
Radiology; 2000 Mar; 214(3):665-70. PubMed ID: 10715027
[TBL] [Abstract][Full Text] [Related]
16. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis.
Kuhle J; Leppert D; Petzold A; Regeniter A; Schindler C; Mehling M; Anthony DC; Kappos L; Lindberg RL
Neurology; 2011 Apr; 76(14):1206-13. PubMed ID: 21346223
[TBL] [Abstract][Full Text] [Related]
17. HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis.
Hensiek AE; Sawcer SJ; Feakes R; Deans J; Mander A; Akesson E; Roxburgh R; Coraddu F; Smith S; Compston DA
J Neurol Neurosurg Psychiatry; 2002 Feb; 72(2):184-7. PubMed ID: 11796767
[TBL] [Abstract][Full Text] [Related]
18. The Multiple Sclerosis Severity Score: associations with MC1R single nucleotide polymorphisms and host response to ultraviolet radiation.
Strange RC; Ramachandran S; Zeegers MP; Emes RD; Abraham R; Raveendran V; Boggild M; Gilford J; Hawkins CP
Mult Scler; 2010 Sep; 16(9):1109-16. PubMed ID: 20670983
[TBL] [Abstract][Full Text] [Related]
19. LncRNAs, MALAT1 and lnc-DC as potential biomarkers for multiple sclerosis diagnosis.
Shaker OG; Mahmoud RH; Abdelaleem OO; Ibrahem EG; Mohamed AA; Zaki OM; Abdelghaffar NK; Ahmed TI; Hemeda NF; Ahmed NA; Mansour DF
Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30514825
[TBL] [Abstract][Full Text] [Related]
20. The cannabinoid receptor 1 gene (CNR1) and multiple sclerosis: an association study in two case-control groups from Spain.
Ramil E; Sánchez AJ; González-Pérez P; Rodríguez-Antigüedad A; Gómez-Lozano N; Ortiz P; Arroyo R; De las Heras V; Vilches C; García-Merino A
Mult Scler; 2010 Feb; 16(2):139-46. PubMed ID: 20007426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
